Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoramidis in Transthyretin-type Cardiac Amyloidosis (CARE ATTR)
NCT07306949Phase 4Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of acoramidis in Transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Alexion Pharmaceuticals. Primary endpoint: Disease Progression Rate as Measured by N-terminal pro-brain-type Natriuretic Peptide and/or Outpatient Diuretic Intensification at 12 months. Started Oct 2025; status: recruiting.
02
Drugs
acoramidis
03
Conditions
Transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT07306949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306949.